Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

External R&D Is Up, But Which Companies Are Reaping The Most Benefit?

Executive Summary

Amgen, Novartis and Lilly are projected to increase sales from externally sourced assets in the coming years, according to a Datamonitor Healthcare analysis, while other big pharma – including frequent acquirer Pfizer and smaller-deal-oriented Bristol – are expected to see that ratio decline compared to sales of internally developed drugs.

Advertisement

Related Content

Biopharma R&D Productivity And Growth 2016: Innovation Performance Improves
In-Licensed Drugs Bring More Growth Than In-House, Study Shows
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel